Brückl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., . . . Laack, E. (2020). Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV: $hWolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker and Eckart Laack. Clinical medicine insights. Oncology, 14, . https://doi.org/10.1177/1179554920951358
Chicago-Zitierstil (17. Ausg.)Brückl, Wolfgang M., et al. "Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-line Therapy Following Second-line Immune-checkpoint-inhibitor Treatment in Patients with Non-small-cell Lung Cancer Stage IV: $hWolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker and Eckart Laack." Clinical Medicine Insights. Oncology 14 (2020). https://doi.org/10.1177/1179554920951358.
MLA-Zitierstil (9. Ausg.)Brückl, Wolfgang M., et al. "Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-line Therapy Following Second-line Immune-checkpoint-inhibitor Treatment in Patients with Non-small-cell Lung Cancer Stage IV: $hWolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker and Eckart Laack." Clinical Medicine Insights. Oncology, vol. 14, 2020, https://doi.org/10.1177/1179554920951358.